- $11.45bn
- $16.05bn
- $4.38bn
Obesity drugmaker Novo Nordisk raises outlook
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
BMO starts Novo Nordisk US shares with "overweight', Street-high PT
Deals of the day-Mergers and acquisitions
Novo Nordisk parent refiles US application on Catalent deal (updated)
Novo Nordisk owner refiles U.S. application for approval of Catalent deal
Media: Ares, Blue Owl lead $4.8 bln private debt for Catalent deal - Bloomberg News
Novo Nordisk-owner to expand in India this year
Highlights: Novo Nordisk hopes to launch experimental obesity drug this decade
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
DNB ups Novo Nordisk on 'game changing' Catalent acquisition
RCS - Germfree - Germfree Announces Appointment of 4 Board Members
Too many drugmakers drool at anti-obesity trough
Wegovy packing supplier Catalent lays off 300 workers
Brief: Catalent Inc Files Non-Timely 10-Q With US SEC - SEC Filing
Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT (updated)
Catalent Inc reports results for the quarter ended in December - Earnings Summary